Efficacy of high-dose methylprednisolone and cyclophosphamide in childhood-onset systemic lupus erythematosus

Background Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Untreated SLE often become progressive and lead to increased risk of mortality. Corticosteroid and cyclophosphamide remain the treatment of choice for severe SLE. Disease activity assessed with SLE Daily Act...

Full description

Saved in:
Bibliographic Details
Main Authors: Putu Ayunda Trisnia (Author), Ketut Dewi KUmara Wati (Author), Komang Ayu Witarini (Author), Ida Bagus Ramajaya Sutawan (Author), Hendra Santoso (Author)
Format: Book
Published: Indonesian Pediatric Society Publishing House, 2020-04-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_d0c5e1b8a7f34652909a56f1f6c08b47
042 |a dc 
100 1 0 |a Putu Ayunda Trisnia  |e author 
700 1 0 |a Ketut Dewi KUmara Wati  |e author 
700 1 0 |a Komang Ayu Witarini  |e author 
700 1 0 |a Ida Bagus Ramajaya Sutawan  |e author 
700 1 0 |a Hendra Santoso  |e author 
245 0 0 |a Efficacy of high-dose methylprednisolone and cyclophosphamide in childhood-onset systemic lupus erythematosus 
260 |b Indonesian Pediatric Society Publishing House,   |c 2020-04-01T00:00:00Z. 
500 |a 0030-9311 
500 |a 2338-476X 
500 |a 10.14238/pi60.3.2020.117-24 
520 |a Background Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disease. Untreated SLE often become progressive and lead to increased risk of mortality. Corticosteroid and cyclophosphamide remain the treatment of choice for severe SLE. Disease activity assessed with SLE Daily Activity Index (SLEDAI). Objective To compare the disease activity of childhood-onset severe SLE at the time of diagnosis, after completion of high dose methylprednisolone, and after three month of cyclophosphamide by using  SLEDAI. Methods This study was conducted in the Division of Pediatric Allergy and Immunology, Department of Child Health, Udayana University/Sanglah Hospital, Denpasar, Bali. Subjects were SLE patient aged 0-18 years who had severe clinical manifestations. Subject received therapy combination of high dose methylprednisolone and cyclophosphamide every 2 weeks for six doses. SLEDAI score was assessed at the time of diagnosis, after completion of high dose methylprednisolone, and after three month of cyclophosphamide. Results During the study period, 51 children were diagnosed as SLE. Twenty-one subjects were included for analysis. Median SLEDAI score at the time of diagnosis was 23 (range 13-39). SLEDAI score after three months of cyclophosphamide was decreased to 2 (range 0-14). Post hoc analysis with Wilcoxon signed-rank test showed the improvement of SLEDAI score at the time of diagnosis and after three months of cyclophosphamide was statistically significant  (Z=-4.016, P<0.0001). Conclusion SLEDAI score reduced after completion of high-dose methylprednisolone and three month of cyclophosphamide therapy. 
546 |a EN 
690 |a sle, childhood-onset, sledai, high-dose methylprednisolone, cyclophosphamide 
690 |a Medicine 
690 |a R 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Paediatrica Indonesiana, Vol 60, Iss 3, Pp 117-24 (2020) 
787 0 |n https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/2313 
787 0 |n https://doaj.org/toc/0030-9311 
787 0 |n https://doaj.org/toc/2338-476X 
856 4 1 |u https://doaj.org/article/d0c5e1b8a7f34652909a56f1f6c08b47  |z Connect to this object online.